NHS England supported reports for monitoring fluoroquinolone use
Posted in News
NHS England supported reports for monitoring fluoroquinolone use.
In late January 2024, the MHRA took additional regulatory action to update the indications for all systemic fluoroquinolones (ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, and ofloxacin) to state they should only be used when other commonly recommended antibiotics are inappropriate.
As a result, the number of Defined Daily Doses (DDDs) for systemic fluoroquinolones (ATC code J01MA) is expected to decrease across the NHS.
The following Define reports show the number of DDDs issued per month, over the preceding 12 months. Each time the report is generated, the preceding 12 months will be used (i.e., a rolling 12 months).
The reports are displayed under Define – Therapeutic Areas – Fluoroquinolone monitoring and usage.
- National DDDs of fluoroquinolones aggregated by region
- Fluoroquinolone DDDs over time by Trust for your ICB
- Aggregated last 12 months of DDD usage separated by chemical at Trust level within your region
- Aggregated last 12 months of DDD usage separated by chemical at Trust level for your ICB
- Aggregated last 12 months of DDDs separated by chemical at Trust level for your region for over-labelled use only
- Aggregated last 12 months of DDDs separated by chemical at Trust level for your ICB for over-labelled use only
- Aggregated last 12 months of DDDs separated by cost centre specialty at Trust level for your region
- Aggregated last 12 months of DDDs separated by cost centre specialty at Trust level for your region over-labelled products only
We are always interested in hearing about how you use our software; if you have any suggestions on reports, please feel free to get in touch at [email protected]